- Report
- April 2025
- 175 Pages
Global
From €4229EUR$4,490USD£3,617GBP
- Report
- April 2023
- 220 Pages
Global
From €3391EUR$3,600USD£2,900GBP
- Report
- March 2025
- 87 Pages
China
From €1696EUR$1,800USD£1,450GBP
- Report
- April 2025
- 50 Pages
Global
From €2496EUR$2,650USD£2,135GBP
- Report
- March 2025
- 211 Pages
China
From €3768EUR$4,000USD£3,222GBP
- Report
- April 2023
- 447 Pages
Global
From €3476EUR$3,690USD£2,972GBP
Sibutramine is an anti-obesity drug that was first approved by the US Food and Drug Administration (FDA) in 1997. It works by inhibiting the reuptake of serotonin and norepinephrine, two neurotransmitters that regulate appetite. It is usually prescribed to people who are obese or overweight and have not been able to lose weight through diet and exercise alone. The drug is available in both oral and injectable forms.
Sibutramine has been used to treat obesity for over two decades, but its use has declined in recent years due to safety concerns. In 2010, the FDA issued a warning about the potential for increased risk of heart attack and stroke associated with the drug. As a result, many countries have removed sibutramine from the market.
Despite the safety concerns, sibutramine remains a popular anti-obesity drug in some countries. It is available in generic form in many countries, including India, Mexico, and Brazil. It is also available in brand name form from several pharmaceutical companies, including Merck, Pfizer, and Novartis. Show Less Read more